|Slideshows|August 4, 2017

8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis

Author(s)Ruby S. Grewal, MD, Tony P. George, MD, FRCPC

The authors compare the clinical features of idiopathic psychosis (eg, schizophrenia) with cannabis-induced psychosis.

View the slides in PDF format.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Using Long-Acting Injectables to Reduce Rates of Relapse: Insights From Erin Crown, MHS, PA-C, Psych-CAQ

ByErin Crown, MHS, PA-C, Psych-CAQ

November 25th 2025

Improving Outcomes in Schizophrenia With Long-Acting Injectables: Insights from the Southern Florida Psychiatry Conference

ByJessica Walters

November 21st 2025

Benefits of Long-Acting Injectable Antipsychotics: An Overview From Southern Florida Psychiatry Conference

ByLeah Kuntz

November 21st 2025

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

ByMichèle Haykal, MD,Nidal Moukaddam, MD, PhD

November 19th 2025

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

ByBrian Miller, MD, PhD, MPH

November 17th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis

Newsletter

Related Content

Using Long-Acting Injectables to Reduce Rates of Relapse: Insights From Erin Crown, MHS, PA-C, Psych-CAQ

Improving Outcomes in Schizophrenia With Long-Acting Injectables: Insights from the Southern Florida Psychiatry Conference

Benefits of Long-Acting Injectable Antipsychotics: An Overview From Southern Florida Psychiatry Conference

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

Polypharmacy in Clozapine-Treated Patients: A Retrospective Analysis

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Epstein Files, the Abuse of Women, and Psychiatry

New Drug Application Submitted for Centanafidine for Treatment of ADHD

Interrelation of Hormones and Adult ADHD

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Lecanemab or Lithium? Compare Benefits, Risks, and Dose